Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07734844 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants With DME - ALTO

Study acronym: ALTO
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment openedv2 Show 4 more changesShow less
    • Trial sites expanded: 0 → 9 locations
    • Primary completion date: Aug 2028 to Aug 31, 2028
    • Study completion date: Aug 2029 to Sep 2029
    • Start date changed from estimate of Aug 2026 to Aug 3, 2026
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants with Diabetic Macular Edema - ALTO
Trial Details
NCT Number NCT07734844
Lead Sponsor Kodiak Sciences Inc
Conditions
(from sponsor)		 Diabetic Macular Edema (DME)
Enrollment 910 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov